Letters NICE and thromboembolism

Lifeblood responds to criticisms in Welfare’s personal view article

BMJ 2012; 344 doi: https://doi.org/10.1136/bmj.e403 (Published 17 January 2012) Cite this as: BMJ 2012;344:e403
  1. Annya Stephens-Boal, executive officer1,
  2. Shelley Webster, chair1,
  3. Kim Carter, trustee1,
  4. Ian M Franklin, trustee1,
  5. Brian Gardner, trustee1,
  6. Simon Hart, trustee1,
  7. Beverley J Hunt, trustee1,
  8. Simon Noble, trustee1,
  9. Robin Offord, trustee1
  1. 1Lifeblood: The Thrombosis Charity, PO Box 58, Llanwrda SA19 0AD, UK
  1. lifeblood.charity{at}gmail.com

Any belief that the charity Lifeblood is controlled by big pharma is a misconception.1 Lifeblood has always striven to be independent; around 58% of our income is from public donations. All funding from drug companies is ring fenced for educational or awareness projects.

In 2008 an article suggested that Lifeblood endorsed a new oral anticoagulant without Lifeblood’s knowledge and consent. Lifeblood reported Boehringer Ingelheim for breaching the …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe